Organization | Prescient Therapeutics, Ltd.

Prescient Therapeutics, Ltd. Report issue

For profit Phase 1 Phase 2

Founded: Melbourne Australia (1987)

Organization Overview

First Clinical Trial

2002

NCT00332930

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2019

Timeline

NOW

Now

Alternative names

Prescient Therapeutics, Ltd. | Virax Pty. Ltd,

Active Ingredients

Drugs in Phase 2 Trials (7)

carboplatin (paraplatin) (1 trial)

cytarabine (cytosar-u) (1 trial)

hiv gag-pol antigens (1 trial)

interferon gamma-1b (actimmune) (1 trial)

recombinant fowlpoxvirus expressing hiv gag-pol antigens (1 trial)

triciribine (2 trials)

triciribine phosphate monohydrate (2 trials)

Drugs in Phase 1 Trials (1)

ptx-100 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Acute Disease (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Leukemia (Phase 2)

Neoplasm Metastasis (Phase 1)

Neoplasms (Phase 1)

Ovarian Neoplasms (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 6
# of Trial APIs: 8